In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.
"HF duration decreased by 73.6% (p = 0.027) frequency by 44.2% (p < 0.001), and severity by 52.6% (p < 0.001). Four women dropped out due to AEs (nausea, rash, somnolence), while 8/16 women who finished the study showed a complete response (Pandya et al. 2004). A large study (Pandya et al. 2005) "
[Show abstract][Hide abstract] ABSTRACT: The cardinal climacteric symptoms of hot flushes and night sweats affect 24-93% of all women during the physiological transition from reproductive to post-reproductive life. Though efficacious, hormonal therapy and partial oestrogenic compounds are linked to a significant increase in breast cancer. Non-hormonal treatments are thus greatly appreciated. This systematic review of published hormonal and non-hormonal treatments for climacteric, and breast and prostate cancer-associated hot flushes, examines clinical efficacy and therapy-related cancer risk modulation. A PubMed search included literature up to June 19, 2014 without limits for initial dates or language, with the search terms, (hot flush* OR hot flash*) AND (clinical trial* OR clinical stud*) AND (randomi* OR observational) NOT review). Retrieved references identified further papers. The focus was on hot flushes; other symptoms (night sweats, irritability, etc.) were not specifically screened. Included were some 610 clinical studies where a measured effect of the intervention, intensity and severity were documented, and where patients received treatment of pharmaceutical quality. Only 147 of these references described studies with alternative non-hormonal treatments in post-menopausal women and in breast and prostate cancer survivors; these results are presented in Additional file 1. The most effective hot flush treatment is oestrogenic hormones, or a combination of oestrogen and progestins, though benefits are partially outweighed by a significantly increased risk for breast cancer development. This review illustrates that certain non-hormonal treatments, including selective serotonin reuptake inhibitors, gabapentin/pregabalin, and Cimicifuga racemosa extracts, show a positive risk-benefit ratio. Key pointsSeveral non-hormonal alternatives to hormonal therapy have been established and registered for the treatment of vasomotor climacteric symptoms in peri- and post-menopausal women.There are indications that non-hormonal treatments are useful alternatives in patients with a history of breast and prostate cancer. However, confirmation by larger clinical trials is required.
[Show abstract][Hide abstract] ABSTRACT: Dans le cancer du sein, la chirurgie est la pierre angulaire du traitement. Néanmoins, des traitements adjuvants comme la
chimiothérapie ou l’hormonothérapie sont nécessaires pour éradiquer les micrométastases. Ces traitements sont á l’origine
de plusieurs effets secondaires. Parmi ces effets secondaires, la ménopause précoce est fréquente, de l’ordre de 53 % á 89
% aprés chimiothérapie (1–3). Chez les femmes non ménopausées avec des tumeurs hormonosensibles, le bénéfice de l’hormonothérapie en termes de survie
globale en association aux autres traitements a été démontré. L’hormonothérapie correspond soit á des traitements suppresseurs
de la fonction ovarienne par castration (chirurgie, radiothérapie ou agonistes de la luteinizing hormone-releasing hormone [LHRH]), soit aux antioestrogénes ou antiaromatases (4). Ces traitements ont donc comme conséquence d’induire des symptômes de la ménopause précoce: bouffées de chaleur, atrophie
génito-urinaire, troubles psychologiques (2, 5, 6). Les bouffées de chaleur sont trés fréquentes chez les femmes non ménopausées traitées pour un cancer du sein et elles sont
invalidantes. En effet, elles diminuent la qualité de vie et la qualité du sommeil (7, 8), d’oú l’importance d’informer les patientes sur les traitements pharmacologiques et non pharmacologiques que l’on peut leur
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.